aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman
aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-26 13:50Accessibility StatementSkip Navigation ATYR Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claim ...